«LUTS/BPH - who treats?». The results of the epidemiologic study


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. In this study an attempt was made to determine some reasons that prompted the urologist to make a choice in favor of particular drug or combination from a wide variety of available drugs. The prescribing habits and subjective evaluation of efficiency and safety of the drugs for the treatment of lower urinary tract symptoms/benign prostatic hyperplasia by the urologists in Russia was analyzed. Materials and methods: a prospective multicenter epidemiological study «LUTS/BPH - who treats?» was carried out in 12 centers using data obtained from May 1 to July 31, 2018 with anonymous survey of 500 urologists living in 9 cities of the Russian Federation. The survey consisted of 46 questions reflecting a level of education, involvement in scientific life of urologic community, membership in various professional organizations, and subjective assessment of safety and efficiency of drugs used in Russian Federation for the treatment of urinary disorders. The obtained data was analyzed for a whole group and further in the subgroups. Results: Alpha-blockers are the most commonly prescribed drugs. These drugs constitute 63.4% of all appointments, followed by the 5-a-reductase inhibitors (23.98%) and combined therapy by the both drugs (24.68%). The most frequently used alpha-blocker is tamsulosin, but professors, MD and urologists, who read special literature at a regular basis, prescribed tamsulosin and silodosin equally. In primary cases and in patients with concomitant cardiac pathology, silodosin was prescribed more commonly in comparison with other alpha-blockers. Conclusion: the results of the study indicate a concordance with global trends in the treatment of these patients. Our data reflect a significant influence of the level of education, work experience and involvement in scientific professional life of urologic community on the choice of a particular drug for the treatment of LUTS/BPH and prove the feasibility of further work which should be aimed at popularization of the modern medical knowledges among the urologists and organization of a process of continuous medical education.

Keywords

Full Text

Restricted Access

About the authors

D. Yu. Pushkar

A.I. Evdokimov Moscow State University of Medicine and Dentistry of Minzdrav of Russia

Email: pushkardm@mail.ru
corresponding member of RAS, MD, professor, Head of the Department of Urology

P. I. Rasner

A.I. Evdokimov Moscow State University of Medicine and Dentistry of Minzdrav of Russia

Email: dr.rasner@gmail.com
MD, professor at the Department of Urology

I. A Aboyan

MBUZ Clinical and diagnostic Center “Zdorovie”

Email: aboyan@center-zdorovie.ru
MD, professor, honored doctor of the Russian Federation

F. R Asfandiyarov

FGBOU VO «Astrakhan state medical university» of the Russian Ministry of Health

MD, associate professor, Head of the Department of Urology

S. V Kotov

N.I. Pirogov RNRMU of Minzdrav of Russia

MD, Head of the Department of Urology and Andrology

M. I Kogan

Rostov State Medical University of Minzdrav of Russia

MD, professor, Head of the Department of Urology

I. A Korneev

Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia

MD, professor, Department of Urology

V. L Medvedev

Kuban State Medical University

MD, professor, Head of the Department of Urology

A. I Neymark

FGBOU VO «Altai State Medical University» of the Ministry of Health of Russia

MD, professor, Head of the Department of Urology and Andrology with a course of Specialized Surgery

A. I Novikov

FGBOU VO North-Western State Medical University named after I.I. Mechnikov

MD, professor at the department of urology

V. N Pavlov

Bashkir State Medical University of the Ministry of Health of the Russian Federation

Email: pavlov@bashgmu.ru
MD, professor, corresponding member of RAS, MD, professor, rector, Head of the Department of Urology with a course of IDPO

A. Yu Tsukanov

FGBOU VO «Omsk State Medical University»

MD, professor, Head of the Urology Course

S. A Shabalkin

A.I. Evdokimov Moscow State University of Medicine and Dentistry of Minzdrav of Russia

Department of Urology

I. S Shormanov

FGBU “Yaroslavl State Medical University” of Minzdrav of Russia

MD, professor, Head of the Department of Urology and Nephrology.

References

  1. Athanasopoulos A. The Role of Antimuscarinics in the Management of Men With Symptoms of Overactive Bladder Associated With Concomitant Bladder Outlet Obstruction: An Update. Eur Urol 2011. http://www. doi: 10.1016/j.eururo.2011.03.054
  2. Hutchison A., Farmer R., Verhamme K. et al. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur Urol. 2007; 51: 207-216.
  3. Пушкарь Д.Ю., Раснер, Котенко Д.В., Герасимов А.Н. Шабалкин С.А. Особенности симптомов нижних мочевыводящих путей у мужчин Московского региона. Результаты эпидемиологического исследования. Урология. 2018;3:20-28
  4. Marberger M. The MTOPS Study: New Findings, New Insights, and Clinical Implications for the Management of BPH. Eur Urol. 2006; Suppl. 5:628-633.
  5. Montorsi F., Roehrborn C., Garcia-Penit J., Borre M., Roeleveld T.A., Alimi J.C., Gagnier P., Wilson T.H. The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination ofAvodart and Tamsulosin (CombAT) study. BJU Int. 2011;107(9):1426-1431.
  6. Пушкарь Д.Ю., Раснер П.И. Урология. Российские Клинические Рекомендации. Глава 1. Симптомы нижних мочевых путей и доброкачественная гиперплазия предстательной железы. Российские клинические рекомендации под ред. Ю.Г. Аляева, П.В. Глыбочко, Д.Ю. Пушкаря М.: МедФорум, 2018. С. 13-43
  7. Гаджиева З.К., Казилов Ю.Б., Мугутдинов Т.М., Казилов Б.Р., Аляев Ю.Г., Абоян И.А. Особенности диагностики и лечения различных нарушений мочеиспускания врачами Республики Дагестан и других регионов Северо-Кавказского и Южного федеральных округов. Урология. 2016;4:48-56
  8. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. European Urology EAU Guidelines. Edn. presented at the EAU Annual Congress Copenhagen 2018. ISBN 978-94-92671-01- http://uroweb.org/ guidelines/compilations-of-all-guidelines/
  9. Juhyun Park, Young Ju Lee, Jeong Woo Lee, Tag Keun Yoo, Jae Il Chung, Seok-Joong Yun, Jun Hyuk Hong, Seong Il Seo, Sung Yong Cho, Hwancheol Son. Comparative analysis of benign prostatic hyperplasia management by urologists and nonurologists: A Korean nationwide health insurance database study. Korean J. Urol. 2015;56:233-239.
  10. Rensing A.J., Kuxhausen A., Vetter J., Strope S.A. Differences in the Treatment of Benign Prostatic Hyperplasia: Comparing the Primary Care Physician and the Urologist. Urol Pract. 2017;4(3):193-199.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies